Pyxis Oncology, Inc. Shareholders' Equity
Pyxis Oncology, Inc. (PYXS) had Shareholders' Equity of $11.44 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $11.44M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $31.27M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $53.41M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $68.78M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $11.44M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $31.27M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $53.41M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $68.78M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $87.64M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $103.10M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $120.75M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $153.68M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $169.79M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $184.16M 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $125.70M 10-K · filed 2026-03-23 | |
| 2023-09-30 | $137.95M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $145.28M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $152.16M 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $160.82M 10-K · filed 2025-03-18 | |
| 2022-09-30 | $188.75M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $211.97M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $233.51M 10-Q · filed 2023-08-11 | |
| 2021-12-31 | $261.31M 10-K · filed 2024-03-21 | |
| 2021-09-30 | -$71.44M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | -$57.59M 10-Q · filed 2022-11-01 | |
| 2021-03-31 | -$50.02M 10-Q · filed 2022-08-15 | -$50.16M 10-Q · filed 2021-11-15 |
| 2020-12-31 | -$15.64M 10-K · filed 2023-03-22 | |
| 2020-09-30 | -$11.09M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$7.91M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | -$4.82M 10-Q · filed 2021-11-15 | |
| 2019-12-31 | -$2.87M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |